Logo image of LEGN

LEGEND BIOTECH CORP-ADR (LEGN) Stock Fundamental Analysis

NASDAQ:LEGN - Nasdaq - US52490G1022 - ADR - Currency: USD

40.41  -0.36 (-0.88%)

After market: 40.79 +0.38 (+0.94%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to LEGN. LEGN was compared to 553 industry peers in the Biotechnology industry. LEGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LEGN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

LEGN had negative earnings in the past year.
In the past year LEGN has reported a negative cash flow from operations.
In the past 5 years LEGN always reported negative net income.
In the past 5 years LEGN always reported negative operating cash flow.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

The Return On Assets of LEGN (-13.50%) is better than 81.92% of its industry peers.
With an excellent Return On Equity value of -21.43%, LEGN belongs to the best of the industry, outperforming 84.45% of the companies in the same industry.
Industry RankSector Rank
ROA -13.5%
ROE -21.43%
ROIC N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

Looking at the Gross Margin, with a value of 65.51%, LEGN belongs to the top of the industry, outperforming 80.65% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for LEGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

4

2. Health

2.1 Basic Checks

LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LEGN has been increased compared to 1 year ago.
LEGN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LEGN is higher compared to a year ago.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 9.02 indicates that LEGN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 9.02, LEGN belongs to the best of the industry, outperforming 84.99% of the companies in the same industry.
A Debt/Equity ratio of 0.35 indicates that LEGN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.35, LEGN is doing worse than 72.69% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z 9.02
ROIC/WACCN/A
WACC9.52%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

LEGN has a Current Ratio of 5.20. This indicates that LEGN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.20, LEGN perfoms like the industry average, outperforming 54.61% of the companies in the same industry.
A Quick Ratio of 5.07 indicates that LEGN has no problem at all paying its short term obligations.
The Quick ratio of LEGN (5.07) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.07
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

7

3. Growth

3.1 Past

LEGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.00%, which is quite impressive.
Looking at the last year, LEGN shows a very strong growth in Revenue. The Revenue has grown by 112.46%.
The Revenue has been growing by 59.90% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-68.75%
Revenue 1Y (TTM)112.46%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%107.52%

3.2 Future

Based on estimates for the next years, LEGN will show a very strong growth in Earnings Per Share. The EPS will grow by 32.04% on average per year.
LEGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 36.75% yearly.
EPS Next Y39.73%
EPS Next 2Y61.99%
EPS Next 3Y45.97%
EPS Next 5Y32.04%
Revenue Next Year64.22%
Revenue Next 2Y59.38%
Revenue Next 3Y51%
Revenue Next 5Y36.75%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LEGN. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 68.16 indicates a quite expensive valuation of LEGN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LEGN indicates a rather cheap valuation: LEGN is cheaper than 88.79% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 37.13, LEGN is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 68.16
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

LEGN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as LEGN's earnings are expected to grow with 45.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y61.99%
EPS Next 3Y45.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LEGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (7/30/2025, 8:25:37 PM)

After market: 40.79 +0.38 (+0.94%)

40.41

-0.36 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners47.77%
Inst Owner Change-0.95%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap7.41B
Analysts84.14
Price Target77.76 (92.43%)
Short Float %9.27%
Short Ratio4.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.01%
Min EPS beat(2)-127.98%
Max EPS beat(2)143.99%
EPS beat(4)2
Avg EPS beat(4)9.55%
Min EPS beat(4)-127.98%
Max EPS beat(4)143.99%
EPS beat(8)5
Avg EPS beat(8)2.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.48%
Min Revenue beat(2)-1.23%
Max Revenue beat(2)2.2%
Revenue beat(4)3
Avg Revenue beat(4)13.65%
Min Revenue beat(4)-1.23%
Max Revenue beat(4)44.46%
Revenue beat(8)4
Avg Revenue beat(8)4.2%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.59%
PT rev (3m)-0.86%
EPS NQ rev (1m)13.46%
EPS NQ rev (3m)31.19%
EPS NY rev (1m)8.26%
EPS NY rev (3m)20.24%
Revenue NQ rev (1m)-3.61%
Revenue NQ rev (3m)-6.56%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-0.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 68.16
P/S 10.18
P/FCF N/A
P/OCF N/A
P/B 7.28
P/tB 7.3
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)0.59
Fwd EY1.47%
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS3.97
BVpS5.55
TBVpS5.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.5%
ROE -21.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.51%
FCFM N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.19%
Cap/Sales 1.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.07
Altman-Z 9.02
F-Score3
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-68.75%
EPS Next Y39.73%
EPS Next 2Y61.99%
EPS Next 3Y45.97%
EPS Next 5Y32.04%
Revenue 1Y (TTM)112.46%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%107.52%
Revenue Next Year64.22%
Revenue Next 2Y59.38%
Revenue Next 3Y51%
Revenue Next 5Y36.75%
EBIT growth 1Y45.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.27%
EBIT Next 3Y58.97%
EBIT Next 5Y37.89%
FCF growth 1Y-3.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.13%
OCF growth 3YN/A
OCF growth 5YN/A